Literature DB >> 26402131

Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma.

Lei Jiang1, Hui Tan, Cedric M Panje, Haojun Yu, Yan Xiu, Hongcheng Shi.   

Abstract

PURPOSE: Although intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy after hepatocellular carcinoma, there are limited data available on PET/CT imaging in ICC. This retrospective study analyzed the role of PET/CT imaging in the evaluation of ICC.
METHODS: FDG PET/CT findings were reviewed in 65 patients with histologically confirmed ICC. PET/CT was evaluated based on visual interpretation and the semiquantitative index of SUVmax and tumor-to-normal liver tissue ratio (TNR), which were consequently further analyzed and correlated with tumor localization, differentiation, size, and serum levels of tumor markers. Forty-five cases also underwent abdominal MRI examinations.
RESULTS: Nineteen patients had hilar ICC, whereas 46 patients had peripheral ICC. Sixty cases of ICC showed elevated FDG uptake with an average SUVmax of 8.3 ± 4.7 and TNR of 3.1 ± 1.7. Five cases located in the hilum were false negative on PET/CT imaging. Compared with hilar ICC, SUVmax and TNR of peripheral ICC were significantly higher (P < 0.05). FDG accumulation correlated with the degree of ICC differentiation. SUVmax and TNR correlated with tumor size, whereas there was no correlation observed with serum levels of carbohydrate antigen 19-9. The sensitivity, specificity, and accuracy of PET/CT and MRI in the diagnosis of regional lymph node metastases were 70.0% versus 50%, 91.7% versus 83.3%, and 81.8% versus 68.2%, respectively. PET/CT upstaged 12.3% and downstaged 3.1% of cases and had no impact on patient management in the remaining 84.6% of cases.
CONCLUSIONS: Combination of FDG PET/CT and abdominal MRI might improve the diagnostic accuracy for ICC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26402131     DOI: 10.1097/RLU.0000000000000998

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  19 in total

Review 1.  Imaging of Cholangiocarcinoma.

Authors:  Susann-Cathrin Olthof; Ahmed Othman; Stephan Clasen; Christina Schraml; Konstantin Nikolaou; Malte Bongers
Journal:  Visc Med       Date:  2016-12-06

Review 2.  Multimodality imaging of intrahepatic cholangiocarcinoma.

Authors:  Kelly Fábrega-Foster; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

3.  Should we expand liver transplant criteria to cirrhotic patients with intrahepatic cholangiocarcinoma?

Authors:  Henrik Petrowsky
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

4.  Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at 18F-FDG-PET/CT: prognostic implication of metabolic parameters and tumor markers.

Authors:  A Sabaté-Llobera; L Gràcia-Sánchez; G Reynés-Llompart; E Ramos; L Lladó; J Robles; T Serrano; J Mestres-Martí; C Gámez-Cenzano
Journal:  Clin Transl Oncol       Date:  2018-07-18       Impact factor: 3.405

5.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

Review 6.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

7.  The influence of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.

Authors:  Youpei Lin; Huanhuan Chong; Guohe Song; Chenhao Zhang; Liangqing Dong; Ling Aye; Fei Liang; Shuaixi Yang; Mengsu Zeng; Guangyu Ding; Shu Zhang; Jieyi Shi; Aiwu Ke; Xiaoying Wang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

8.  Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Authors:  Satoshi Takeuchi; Eric M Rohren; Reham Abdel-Wahab; Lianchun Xiao; Jeffrey S Morris; Homer A Macapinlac; Manal M Hassan; Ahmed O Kaseb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-12       Impact factor: 9.236

9.  18F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma.

Authors:  Lei Jiang; Yan Huang; Qiying Tang; Qingping Zhao; Yuan Li; Xiaodong Wu; Huoqiang Wang
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

10.  Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma.

Authors:  Gauthier Delaby; Bahar Ataeinia; Jennifer Wo; Onofrio Antonio Catalano; Pedram Heidari
Journal:  Abdom Radiol (NY)       Date:  2021-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.